Phase 4Active, not recruiting
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR)
- Sponsor
- Cedars-Sinai Medical Center (Academic or other)
- Enrollment
- 2,476 enrolled
- Conditions
- Coronary Artery Disease
- Interventions
- High dose potent statin; ACE-I (lisinopril) or ARB (losartan); Aspirin 81 enteric coated tablet daily; Lifestyle Counseling; Quality of Life Questionnaires
- Ages
- adults, older adults
- Registry
- NCT03417388
Full record on ClinicalTrials.gov
From the registry
The Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) trial is a multicenter, prospective, randomized, blinded outcome evaluation (PROBE design) evaluating intensive statin/ACE-I (or ARB)/aspirin treatment (IMT) vs. usual care (UC) in 4,422 symptomatic women patients with symptoms and/or signs of ischemia but no obstructive CAD. The hypothesis is that IMT will reduce major adverse coronary events (MACE) 20% vs. UC. The primary outcome is first occurrence of MACE as death, nonfatal MI, nonfatal stroke/transient ischemic attack (TIA) or hospitalization for heart failure or angina. Secondary outcomes include quality of life, time to "return to duty"/work, health resource consumption, angina, cardiovascular (CV) death and primary outcome components. Events will be adjudicated by an experienced Clinical Events Committee (CEC). Follow-up was planned to be 3-years using 50 sites: primarily VA and Active Duty Military Hospitals/Clinics and a National…
Primary outcomes
- The primary outcome is MACE, defined as first occurrence of all-cause death, non-fatal MI, non-fatal stroke, or hospitalization for angina or HF.
History
Study completion expected
Completion moved to Feb 15, 2025
, from May 31, 2024 to Feb 15, 2025
Last registry update
Primary completion
Started
Registered